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Abstract
Background: 15-deoxy-D 12,14- Prostaglandin J2 (15dPGJ2) inhibits Nuclear factor kappa B (NF-kB) in human myocytes and
amniocytes and delays inflammation induced preterm labour in the mouse. 15dPGJ2 is a ligand for the Chemoattractant
Receptor Homologous to the T helper 2 cell (CRTH2), a G protein-coupled receptor, present on a subset of T helper 2 (Th2)
cells, eosinophils and basophils. It is the second receptor for Prostaglandin D2, whose activation leads to chemotaxis and
the production of Th2-type interleukins. The cellular distribution of CRTH2 in non-immune cells has not been extensively
researched, and its identification at the protein level has been limited by the lack of specific antibodies. In this study we
explored the possibility that CRTH2 plays a role in 15dPGJ2-mediated inhibition of NF-kB and would therefore represent a
novel small molecule therapeutic target for the prevention of inflammation induced preterm labour.
Methods: The effect of a small molecule CRTH2 agonist on NF-kB activity in human cultured amniocytes and myocytes was
assessed by detection of p65 and phospho-p65 by immunoblot. Endogenous CRTH2 expression in amniocytes, myocytes
and peripheral blood mononuclear cells (PBMCs) was examined by PCR, western analysis and flow cytometry, with
amniocytes and myocytes transfected with CRTH2 acting as a positive control in flow cytometry studies.
Results: The CRTH2 agonist had no effect on NF-kB activity in amniocytes and myocytes. Although CRTH2 mRNA was
detected in amniocytes and myocytes, CRTH2 was not detectable at the protein level, as demonstrated by western analysis
and flow cytometry. 15dPGJ2 inhibited phospho-65 in PBMC’S, however the CRTH2 antagonist was not able to attenuate
this effect. In conclusion, CRTH2 is not expressed on human amniocytes or myocytes and plays no role in the mechanism of
15dPGJ2-mediated inhibition of NF-kB.
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Introduction
Preterm delivery complicates 6–11% of pregnancies in Europe
and North America [1]. Preterm labour is a heterogenous
condition [2], however there is a strong association between
infection and inflammation, particularly in early preterm deliveries
[3]. Despite our increased awareness of this association [4], limited
progress has been made in drug development targeted towards
anti-inflammatory pathways involved in infection/inflammation
induced preterm labour.
Nuclear factor Kappa B (NF-kB) is a transcription factor that
plays a central role in controlling the inflammatory response [5].
Human T cell NF-kB activity is suppressed during pregnancy,
which likely explains the altered bias from the Th1 to Th2
cytokine ratio [6]. The NF-kB signaling pathway also plays an
important role in the process of human labour [7]. Expression of
the p65 subunit shows a marked increase in the fundal
myometrium during labour [8], associated with an increase in
DNA binding activity [9]. NF-kB activity is also increased in
amnion during labour [10], with pre-labour samples showing
varying degrees of p65 expression, which is likely to reflect the
physiological transition that precedes parturition [11]. Many
labour associated genes, such as the phospholipases A2 isoenzymes
(cPLA2) [12], cyclooxygenase-2 (COX-2), interleukin-8 (IL-8), IL-
6, and matrix metalloproteinases (MMPs) [7] are transcriptionally
regulated by NF-kB. Pro-inflammatory cytokines such as IL-1b
and TNF-a are both regulated by and can activate NF-kB giving
rise to a positive feed forward loop and thus further activating the
NF-kB regulated genes [13].
Given the importance of NF-kB in the regulation of inflamma-
tion and labour, it represents an important potential therapeutic
target for the prevention of preterm labour and the neonatal
sequale as a direct result of both inflammation and prematurity.
We have previously investigated the potential of 15-deoxy D12,14
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Prostaglandin J2 (15dPGJ2), an anti-inflammatory cyclopenentone
prostaglandin, in the prevention of inflammation/infection
induced preterm labour. 15dPGJ2 inhibits IL-1b stimulated NF-
kB in human amniocytes and myocytes, independently of PPAR-c
[14], and reduces the percentage of peripheral blood mononuclear
cells producing IFN-c and TNF-a during pregnancy [15].
Moreover, in a mouse model of lipopolysaccharide-induced
preterm labour, 15dPGJ2 delays preterm labour and increases
pup survival from 30% to 95% [16]. The precise mechanism of
NF-kB inhibition is still not fully understood. 15dPGJ2 is also a
ligand for the second Prostaglandin D2 (PGD2) receptor,
Chemoattractant receptor-homologous molecule expressed on T
helper 2 cells (CRTH2), and binds to it with equivalent affinity to
PGD2 as the specific CRTH2 agonist DK-PGD2 [17].
The human CRTH2 gene is located at chromosome 11q12, its
transcript length is 2.9 kb consisting of two exons and one intron
[18]. It was first named and described by Nagata and colleagues as
being expressed on Th2 but not Th1 clones following a gene
expression search method [19]. Subsequently it was entitled
‘receptor D2’, a second novel receptor of Prostaglandin D2
(PGD2) [20] as well as ‘GPR44’ following a search for novel G
protein coupled receptors [21]. It is now apparent that these are
the same receptor, which is also referred to as the cluster
differentiation protein CD294 [22]. As a typical GPCR it has
seven putative transmembrane domains, with two potential
glycosylation sites at its N terminus, and a long cytoplasmic tail
with multiple phosphorylation sites [19]. Despite PGD2 acting as a
ligand to both the DP1 and CRTH2 receptor, there is a lack of
homology between their sequences and their downstream effects
differ substantially. CRTH2 is expressed on T helper 2 cells,
eosinophils and basophils [23]. The CD4+ T cells that express
CRTH2 secrete interleukins typical of Th2 cells; IL-4, IL-5, IL-13,
and little if any INF-c [19]. CRTH2 is not expressed on human
Th1 cells, and this has led to CRTH2 becoming a cell
differentiation marker of Th2 cells [19].
CRTH2 mRNA expression has been described in a number of
tissue types, with high expression in heart, brain, stomach, small
intestine, liver, thymus, and placenta and moderate expression in
the colon, uterus, pancreas, prostate and peripheral blood
leukocytes [24]. Other groups have demonstrated CRTH2 mRNA
expression at the cellular level in non-immune cells including
osteoblasts [25], chondrocytes [26] bronchial epithelial cells [27]
and keratinocytes [28]. However, studies of CRTH2 expression at
the protein level in non-immune cells are limited, probably due to
the lack of specific commercially available antibodies available for
detection of CRTH2 using techniques other than flow cytometry.
The protein expression profile of CRTH2 in human amniocytes
and myocytes has not been investigated to date.
In this study we explored the potential role of CRTH2 in
15dPGJ2 mediated NF-kB inhibition. We examined the effect of a
small molecule CRTH2 agonist (Pyl A) on NF-kB activity in
human cultured amniocytes and myocytes and examined both the
mRNA and protein CRTH2 expression profile in these cell types.
Materials and Methods
Ethics Statement
Ethical approval was obtained for placenta (Ref 2002/6283)
and myometrium (Ref 3358) from the ethics committees of the
Imperial College Healthcare NHS Trust/Imperial College or
from the South East London ethical committee for peripheral
blood (Ref 10/H0805/54), and in accordance with Imperial
College NHS Healthcare Trust Research and Development.
Written consent was obtained from all subjects. All clinical
investigation was conducted according to the principles expressed
in the Declaration of Helsinki.
Reagents
15dPGJ2 was purchased from Cayman Chemicals (Ann Arbor,
MI). The small molecule CRTH2 agonist, Pyl A, was synthesised
commercially by Oxygen Healthcare, (Cambridge, London) based
on the L-888,607 compound from Merck Frosst Centre for
Therapeutic Research (Quebec, Canada) [29]. The CRTH2
antagonist GSKCRTH2X was obtained from Glaxo Smith Kline,
(London, UK). IL-1b was from R&D Systems (Abingdon, UK).
Antibodies against phospho-p65 (Ser 536), p65 and CRTH2 for
western analysis were purchased from Cell Signaling Technology
(Beverly, MA), Santa Cruz Biotechnology (Santa Cruz, CA) or
Santa Cruz and ProSci Incorporated (Poway, CA) respectively.
The b-actin antibody was purchased from Sigma (Gillingham,
UK). The flow cytometry antibodies and their isotype controls for
CRTH2 were purchased from were from Beckman Coulter (High
Wycombe, UK), and CD4 from BD Pharminogen (Oxford, UK).
All primers were from Thermo-Scientific (Waltham, MA). For
cloning and transfection experiments the sources of reagents were
as follows: the intermediate vector pCRH -BluntII-TOPOH,
Invitrogen Life Technologies (Grand Island NY); pSG5 expression
vector, Agilent Technologies (Wokingham, UK); T7 TNT
Coupled Reticulocyte Lysate System, Promega (Madison, WI);
GeneJuiceH transfection reagent, Novagem (Hertford UK); and
AMAXA Basic Nucleofector Smooth Muscle Cell Kit, Lonza
(Basel, Switzerland).
Cell Culture
Placentas and myometrial biopsies were collected at the time of
pre-labour caesarean section, and blood was taken from non
pregnant women.
Preparation of amnion epithelial cells. Amnion was
separated from the choriodecidua, cut into strips and washed in
phosphate buffered saline (PBS). It was then incubated 0.5 mM of
EDTA-PBS for 15 mins at room temperature, and washed in PBS.
The intracellular matrix was digested in pre-warmed Dispase at
2 g/L in PBS for 45 mins at 37uC. The epithelial cells were then
isolated by shaking the amnion strips vigorously in Dulbecco’s
modified Eagle’s medium, DMEM for 3 mins, then pelleted by
centrifugation for 10 mins at 2000 rpm. Cells were resuspended in
DMEM containing 10% fetal calf serum, 2 mM/L L-glutamine,
100 U/ml Penicillin and 100 mg/ml of Streptomycin and grown
to confluence in T25 flasks at 5% CO2. Cells were cultured for 24
hours until confluent.
Preparation of myocytes. Myometrial biopsies were taken
from the upper margin of lower segment incisions during elective
caesarean sections. Tissue was washed in PBS and mechanically
dissected with two sterile blades to form a paste-like texture. Cells
were isolated by incubating with 15 mg of Collagenase 1A, 15 mg
of Collagenase X and 50 mg of BSA in 30 mls of PBS for 45 mins
at 37uC. The suspension was filtered through a cell strainer and
centrifuged at 400 g for 5 mins. The cells were resuspended and
cultured in DMEM as described above. Myocytes were cultured
until confluent. Passage one myocytes were used for transfection
studies and passage 0–4 for studies of endogenous CRTH2.
Preparation of placenta and choriodecidua. A biopsy of
placenta and choriodecidua were snap frozen and ground in liquid
nitrogen in preparation for mRNA extraction.
Preparation of peripheral blood mononuclear
cells. Blood was diluted 1:1 with phosphate buffered saline
(PBS) and carefully layered onto Ficoll-PaqueTM PLUS (GE
Healthcare, Uppsala, Sweden) before centrifuging at 400 g for
CRTH2 Is Not Expressed on Amniocytes and Myocytes
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40 mins at room temperature. After centrifugation, the halo
containing PBMCs was carefully transferred into a clean
centrifuge tube and washed twice with 7 ml of PBS. After
centrifugation (400 g for 10 mins), the cell pellet was resuspended
in extraction buffer or RPMI 1640 culture medium (Invitrogen
Life Technologies, Grand Island, NY) culture medium.
Cell Treatment
A dose response with the CRTH2 agonists 15dPGJ2 and Pyl A
from 0.1 mM-32 mM for 2 hrs was used to determine the effect on
NF-kB activity in IL-1b treated amniocytes and myocytes.
Stimulation was required with 1 ng/ml of IL-1b, since basal
activity in pre-labour amnion and myometrium is low [14]. Based
on previous work with 15dPGJ2 on amniocytes, myocytes [14]
and PBMC’s [15], 32 mM of 15dPGJ2 was used for determining
the effect of NF-kB activity in PBMC’s. Prior to treatment with
15dPGJ2, cells were pre-treated with 2 mM of GSKCRTH2X (a
CRTH2 antagonist) or vehicle for 45 mins.
PCR
Total RNA was extracted using TRIzolH (Invitrogen) and
reverse transcribed by Superscript III (Invitrogen). Taq Po was
used for qualitative PCR. CRTH2 was detected using qualitative
PCR with the Primer sets A and B (Table 1) under cycling
conditions of; 95uC for 3 min, amplification by 35 cycles of PCR
(94uC, 1 min; 67uC, 1 min; 72uC, 2 min) for set A and 95uC for
3 min, amplification by 40 cycles of PCR (94uC, 1 min; 63uC,
1 min; 72uC, 2 min) for set B with AB1 StepOne. Products of
quantitative PCR were also qualitatively assessed on an agarose gel
having been amplified with primer set C (Table 1) with
SYBRGreen PCR Master mix (Applied Biosystems) under the
following cycling conditions of activation at 50uC for 2 min with
40 cycles of (95uC, 1 min; 95uC, 15 s; 60uC, 1 min). Peripheral
mononuclear blood cell cDNA was used to amplify a 1.188 kb
CRTH2 transcript using primer set D with activation at 95uC for
3 min and 36 cycles of (94uC, 1 min; 75uC, 1 min; 72uC, 2 min).
The primer sets produced amplicons where the intron/exon
boundary was crossed wherever possible. Non-template controls
and reverse transcriptase negative controls were used. Products
were subjected to gel electrophoresis and detected by staining with
Sybersafe (Invitrogen) to assess for correct product size.
Sodium Dodecyl Sulfate Polyacrylamide Gel
Electrophoresis (SDS-PAGE) and Western Blotting
Protein was extracted from cells with whole cell lysis buffer
(Cell Signalling, Beverly, MA) and 5 ml/ml of protease inhibitor
(Sigma). Cells were incubated with ice cold buffer for 5 mins
and centrifuged for 20 mins at 13,000 rpm at 4uC. Protein
extraction from tissue was performed by homogenising in whole
cell lysis buffer prior to the above incubation steps. For nuclear
protein extraction cells were lysed in Buffer A (10 mM HEPES,
10 mM KCL, 0.1 mM EGTA, 0.1 mM EDTA, 1 mM DTT,
1%(v) NP-40 with protease inhibitor), with the cytosolic fraction
collected following centrifugation at 13,000 rpm for 60s at 4uC.
The pellet was then resuspended in Buffer B (10 mM HEPES,
10 mM KCL, 0.1 mM EGTA, 0.1 mM EDTA, 2MM DTT,
400 mM NaCl and 1% v/v NP-40 and protease inhibitors),
incubated on a shaker for 15 mins at 4uC, and then centrifuged
at 13,000 rpm for 5 mins at 4uC. Prior to SDS-PAGE, protein
concentrations were determined using the BIORAD quantifica-
tion assay measuring absorbance at 655 nm. Between 15 and
50 mg of extracted protein per sample, was resolved by SDS-
PAGE and subsequently transferred onto polyvinyl difluoride
(PVDF) membranes (GE Healthcare) at 100 V constant at 4uC.
Following transfer, the membrane was then blocked in 5% (wt/
vol) milk in tris-buffered saline (TBS) supplemented with 0.1%
Tween 20 (TBST) for 1 h. The membrane was then probed
with the relevant primary antibody followed by the appropriate
secondary antibody under conditions specified in (Table 2).
Chemiluminescence detection was then carried out with ECL
Plus (GE Healthcare) and the membranes developed using a
high Performance chemiluminescence film (GE Healthcare).
Blots were scanned and densitometry was performed with
ImageJ (v1.44p).
Cloning
Human peripheral leukocytes were used to extract mRNA and
to reverse transcribe to cDNA with random hexamers with
Superscript III according to manufacturer’s instructions (Invitro-
gen Life Technologies). A 1.18 kB CRTH2 transcript of the
coding region was amplified with primers which introduced BamH
I digest sequence upstream of the CRTH2 coding sequence and a
BGL II restriction digest sequence downstream (Table 2). The
transcript was cloned into an intermediate TOPO Vector (pCRH -
BluntII-TOPOH) according to manufacturer’s instructions (Invi-
trogen Life Technologies). The plasmid was digested at the
BamH1 and BglII sites, run on a 1% DNA Agarose gel, cut and
purified using the Geneclean kit for insertion into the pSG5
expression vector. Plasmids were digested and the insert was
purified for sequencing to confirm that CRTH2 was present and
in frame. The pSG5 expression vector was selected since this has
previously been shown to lead to high and stable expression of
multiple proteins in myocytes [30].
In vitro Transcription Translation and Transfection
CRTH2 expression in a cell free system was examined with
the T7 TNT Coupled Reticulocyte Lysate System. The TNT
kit was used as per manufacturer’s instructions (Promega) to
produce CRTH2 with both cold Methionine and radioactive
35S Methionine for detection by both western analysis and x-ray
film respectively. The progesterone pSG5 expression vector, a
Table 1. The primer sequences used for amplification of CRTH2.
Forward 59 Anti-sense 59 bp
Set A CCTCTGTGCCCAGAGCCCCACGATGTCGGC CACGGCCAAGAAGTAGGTGAAGAAG 309
Set B CTGCCCTTCTTCACCTACTTCTTGGC GTGTCCCGGAACACGAAATAGGGCAC 265
Set C CCTCTGTGCCCAGAGCCCCACGATGTCGGC ATGTAGCGGATGCTGGTGTTG 114
Set D* 59GGATCCATGTCGGCCAACGCCACACTGAAGCC (*Includes
BAMH I site)
AGATCTCTAACTCGAGGTGCTGCTCAGCGCCC
(*Includes BGL II site)
1188
doi:10.1371/journal.pone.0050734.t001
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kind donation of Dr Yun Lee, served as a positive control for
the efficiency of the transcription-translation reaction. For
transfection of CRTH2 into amniocytes; primary amnion
epithelial cells were cultured until 80% confluence. GeneJuiceH
transfection reagent was used according to manufacturer’s
guidance (Novagem) with 1 mg of DNA per well. For
transfection of CRTH2 into myocytes; myometrial smooth
muscle cells were cultured until 100% confluence. The AMAXA
Basic Nucleofector Smooth Muscle Cell Kit was used as per
manufacturer’s instructions (Lonza). Electroporation was per-
formed with the Nucleofector Program using Program A-033.
GFP was used as a positive control for the transfection
efficiency. Gene expression of Green Fluorescent Protein
(GFP) was determined by fluorescent microscope on days 1
and 2 post transfection. Gene expression of CRTH2 was
determined by Flow cytometry on days 1 and 2 post
transfection.
Flow Cytometry for Detection of CRTH2
PBMC, amniocyte and myocyte pellets were resuspended in
staining buffer (1% Fetal Calf Serum, 0.09% Sodium Azide in
PBS). Cells were incubated in the dark for 1 h at 37uC with 20–
40 ml of CRTH2-PE. PBMCs were also incubated with 3 ul of
CD4-APC. Mouse IgG1 k –APC and Rat IgG2a-PE were used as
isotype controls. After incubation, the PBMC suspension was
washed twice in 1 ml of PBS and then resuspended in PBS for
analysis. The FACSCalibr flow cytometer was used for CRTH2
detection and settings were as follows: PBMCs; Forward scatter E0
Voltage, 1.00 Amp gain Lin, and Side scatter of 329 Voltage,
1.00 Amp gain Lin, amniocytes; Forward Scatter E1; Voltage
4.77; Amp gain Lin; Side scatter of 320; Voltage 1.00; Amp gain
Lin; FL2 347 log, Myocytes; Forward Scatter E1; Voltage 4.37;
Amp gain Lin; Side scatter of 197; Voltage log; FL2 350 log.
Results are expressed as percentage of cells expressing the receptor
and mean fluorescence intensity of receptor expression. The
geographical mean was used since data was collected on a
logarithmic scale and is a better indicator of the central tendency
of the population.
Statistical Analysis
Experimental sample groups consisted of 3–6 biological
replicates. Statistical analysis was performed with Graph-Pad
Prism (v5.0; GraphPad Software, San Diego, CA). ANOVA of
repeated measures was conducted where appropriate, with
Bonferroni’s multiple comparison’s test for post-hoc analysis.
Samples with P,0.05 was considered to be statistically
significant.
Results
The CRTH2 Agonist 15dPGJ2 Inhibits IL-1b Induced NF-
kB Activity in Human Amniocytes and Myocytes but the
CRTH2 Agonist Pyl A does not Replicate this Effect
We have previously shown that 15dPGJ2 inhibits IL-1b induced
NF-kB activity in human amniocytes and myocytes in a
mechanism independent of PPAR-c [14]. Here we initially
replicated these results showing a significant reduction in IL-1b
induced NF-kB, as determined by nuclear p65, to below basal
levels in amniocytes at 32 mM and in myocytes from 16 mM
(Figure 1A and 1B). If CRTH2 is expressed in amniocytes and
myocytes and is the mechanism of action of 15dPGJ2, we would
expect a small molecule CRTH2 agonist to replicate the effect of
Table 2. The incubation conditions and the catalogue numbers for all antibodies used.
Primary antibody Secondary antibody Cat number
P-p65 (Ser536) 1:1000 Overnight at 4uC Anti-rabbit; 1:2000 1 hr RT Cat 3033s
p65 1:1000 Overnight at 4uC Anti-mouse; 1:200 1 hr RT Cat no 8008
CRTH2 1:200 Overnight at 4uC Anti-goat: 1:2000 1 hr RT Cat no. 23092
CRTH2 1:500 Overnight at 4uC Anti-rat; 1:3000 1 hr RT Cat no. 2178
CRTH2 1:500 Overnight at 4uC Anti-rabbit; 1:2000 1 hr RT Cat no. PR-4029
b-actin 160:000 30 minutes at RT Anti-mouse; 20:1000 15 mins RT Cat no. A 2228
doi:10.1371/journal.pone.0050734.t002
Figure 1. 15dPGJ2 reduced NF-kB p65 activity in amniocytes and myocytes. Protein was extracted from IL-1b stimulated and 15dPGJ2
treated cells and levels of nuclear p65 were examined using immunoblotting. A dose response of 0.1–32 mM of 15dPGJ2 was used (n = 3).
Representative immunoblots are shown for amniocytes, (A), myocytes (B). Immunoblots were re-probed for b-actin as an internal loading control.
doi:10.1371/journal.pone.0050734.g001
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15dPGJ2 We therefore examined the effect of the CRTH2 agonist
Pyl A on IL-1b induced NF-kB in amniocytes and myocytes to
determine if the small molecule agonist could replicate the effects
of 15dPGJ2. NF-kB activity was assessed by examining nuclear
p65 and phospho-p65 by immunoblot. There was no difference in
IL-1b stimulated NF-kB activity seen with Pyl A treatment in
either cell type. Representative immunoblots for amniocytes and
myocytes are shown in Figures 2A and 2B respectively, with
densitometric analysis taking into account b-actin loading controls
seen in Figures 2C–F.
CRTH2 mRNA is Expressed in Amniocytes and Myocytes
The absence of Pyl A mediated inhibition of NF-kB in
amniocytes and myocytes led us to question if this was due to a
Figure 2. Pyl A has no effect on NF-kB p65 activity in amniocytes and myocytes. Protein was extracted from IL-1b stimulated and Pyl
treated cells and levels of nuclear p65 and phosphorylated p65 (p-p65) were examined using immunoblotting. A dose response of 0.1–32 mM of Pyl A
was used. Representative immunoblots are shown for amniocytes, (A) and myocytes (B). Immunoblots were re-probed for b-actin as an internal
loading control. Densitometric analysis of the immunoblots was conducted revealing no effect of Pyl A on p65 or p-p65 in amniocytes (C, E) or
myocytes (D, F). NS = non-stimulated (non-IL-1b treated cells). Effect of treatment was examined for statistical significance using ANOVA of repeated
measures with Bonferroni’s multiple comparison test; *P,0.05.
doi:10.1371/journal.pone.0050734.g002
CRTH2 Is Not Expressed on Amniocytes and Myocytes
PLOS ONE | www.plosone.org 5 November 2012 | Volume 7 | Issue 11 | e50734
lack of expression of CRTH2 in these cells, or, alternatively that
there is no role for CRTH2 in 15dPGJ2 mediated inhibition of
NF-kB. Accordingly, CRTH2 mRNA and protein expression of in
amniocytes and myocytes was examined by PCR and western
analysis. CRTH2 mRNA was detected in amniocytes and
myocytes as well as choriodecidual tissue and placental tissue
with two primer sets. Placenta served as a positive control [24] and
non-template negative controls were included (Figure 3A and 3B).
A third primer set was used as confirmation of consistent
expression in amniocytes and myocytes with reverse transcriptase
negative controls and PBMCs as a positive control (Figure 3C).
N= 6 biological replicates were examined.
CRTH2 is not Expressed at the Protein Level in
Amniocytes and Myocytes
Western analysis of endogenous CRTH2. CRTH2 ex-
pression at the protein level was then examined by immunoblot
using the CRTH2 antibody Sc-23092 (Figure 4). 50 mg of total
protein derived from PBMC whole cell lysate, amniocytes,
myocytes was used. Multiple bands are seen in both the positive
control (PBMCs) and in the amniocyte and myocyte lanes. A band
appears at Mr,34 000 in amniocytes, faintly in the myocyte lane,
but is absent in the positive control PBMCs lane. However, the
strongest bands appear at Mr,15 000 and at just above Mr,43
000 in all lanes. No culture dependent effect was seen as
demonstrated by myocytes from passage 0–4 in panel C,
Figure 4. With the absence of CRTH2 detection in the positive
control, we cannot determine the presence or absence of
endogenous CRTH2 in amniocytes and myocytes from this
immunoblot alone.
Detection of CRTH2 in the pSG5 expression
vector. With the possibility of very low endogenous protein
expression of CRTH2 explaining the reason for the antibody
failing to detect CRTH2 in the positive control of the immunoblot
in Figure 4, we cloned and synthesised CRTH2 using an in-vitro
transcription translation kit to form a highly concentrated CRTH2
protein lysate to serve as a positive control. A band at Mr,34 000,
consistent with the reported expected size could be clearly
observed following detection of radioactive 35S Methionine by x-
ray film (Figure 5A). The protein lysate was then loaded and
transferred onto immunoblots and probed with three commer-
cially available antibodies designed for western blotting. No band
was detected at Mr,34 000, with non-specific bands appearing
also in the negative control of the TNT kit without plasmid DNA
(Figure 5B–D).
Detection of endogenous CRTH2 by flow
cytometry. Several studies have used commercially available
antibodies for flow cytometry successfully for the detection of
endogenous CRTH2 [27,31,32]. Similarly, we were able to detect
endogenous CRTH2 by flow cytometry on human lymphocytes.
Lymphocytes were gated based on forward and side scatter profile.
A representative cytogram is shown with CRTH2+/CD4+ cells
seen in the right upper quadrant (Figure 6A). 1.6% of lymphocytes
were CRTH2+/CD4+, and 0.57% were CRTH2+/CD42. A
representative histogram of cells with no staining, isotype control
and CRTH2 staining is shown, with the mean fluorescence
intensity of 157.80 compared to 22.8 in the isotype control sample
(Figure 6B). No CRTH2 expression was seen in amniocytes or
myocytes, with a mean fluorescence intensity of 14.41 with
labelling compared to 15.71 for the isotype in amniocytes; and
69.69 with labelling compared to 69.30 in the isotype control
labelled myocytes (Figure 6C and 6D), n= 6. Table 3 summarises
the mean fluorescence intensity and percentage of cells expressing
CRTH2 in the gated populations.
Detection of transfected CRTH2 in amniocytes and
myocytes by flow cytometry. Since we could not detect
CRTH2 in amniocytes or amniocytes by flow cytometry we
transfected in a CRTH2 expression vector to confirm that
endogenous CRTH2 could have been detected if present. CRTH2
was detected in amniocytes and myocytes transfected with
CRTH2, as seen by an increase in the mean fluorescence
intensity. Representative histograms are shown for transfected
samples, with isotype controls for amniocytes (Figure 7A) and
myocytes (Figure 7B). The mean fluorescence intensity increased
from 87.75 in the isotype control to 143.49 in amniocytes, and
from 68.84 to 96.97 in myocytes. A GFP transfection control is
shown to confirm adequate transfection efficiency (Figure 7C).
Table 4 summarises the mean fluorescence intensity and
percentage of cells expressing CRTH2 in the gated populations.
15dPGJ2 Inhibits Basal NF-kB Activity in PBMC’s in a
Mechanism Independent of CRTH2
Thus far we have demonstrated that CRTH2 is not expressed at
detectable levels in amniocytes and myocytes. We therefore
proposed that CRTH2 does not play a role in 15dPGJ2-mediated
inhibition of NF-kB. To confirm this we treated PBMCs with
15dPGJ2 with or without the CRTH2 antagonist, GSKCRTH2X
(n= 6). 15dPGJ2 showed complete inhibition of phospho-65
(P,0.0001) which was not attenuated by pre-incubation with the
CRTH2 antagonist (Figure 8).
Discussion
Preterm birth accounts for 70–75% of neonatal morbidity and
mortality [33]. In 80–85% of cases of spontaneous preterm labour
,28 weeks there is evidence of intrauterine infection [34]. The
presence of inflammation can increase the risk of neonatal
morbidity, independently of prematurity [35]. Inflammatory
Figure 3. CRTH2 mRNA is expressed in amniocytes and myocytes. mRNA was isolated from cultured amniocytes, myocytes, PBMCs,
choriodecidual and placental extracts and converted to cDNA (n= 6). Qualitative PCR was used with three primer sets to amplify CRTH2 showing
product sizes of 309 bp, 265 bp, and 114 bp. Non-template and reverse transcriptase negative controls were used and mRNA from placenta,
choriodecidua and peripheral blood mononuclear cells were used as a positive controls. (A,B): Non-template control (lane 1), amniocytes (lane 2),
choriodecidua (lane 3), myocytes (lane 4), placenta (lane 5); (C): Reverse transcriptase controls (lanes 1,3,5,7,9), PBMCs (lane 2), amniocytes (lanes 4,6),
myocytes (lanes 8,10).
doi:10.1371/journal.pone.0050734.g003
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Figure 4. Western blot of protein lysate from PBMCs, amniocytes, myocytes. 50 mg of whole cell lysate from PBMCs, amniocytes, myocytes
were subject to western analysis. Membranes were probed with the primary antibody -SC-23092 to detect a Mr,34 000 product (A; Lanes 1–3). The
secondary antibody control blot is also shown (B; Lanes 1–3). b-actin was used as a loading control. Lane 1 = PBMCs, lane 2 = amniocytes, lane
3 =myocytes. Multiple bands are seen on the blot. A band appears at Mr,34 000 in amniocytes, faintly in the myocyte lane, but is absent in the
positive control PBMCs lane. However, the strongest bands appear at Mr,15 000 and at just above Mr,43 000 in all lanes. Myocytes from passage
zero, one, two, three and four (lanes 1–5 respectively) were also examined for CRTH2 expression showing a very faint band at Mr,34 000, with no
effect of passage number (C).
doi:10.1371/journal.pone.0050734.g004
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cytokines, produced in association with infection, can activate the
transcription factor NF-kB. Since NF-kB controls the expression
of many labour associated genes and pro-inflammatory cytokines,
targeting the inhibition of NF-kB seems attractive to prevent both
infection induced preterm labour and the associated risk of brain
injury associated with inflammation. In this study we explored the
possibility that CRTH2 plays a role in 15dPGJ2-mediated
inhibition of NF-kB both at a local level in cells of the maternal
fetal interface; amniocytes and myocytes, and systemically in
peripheral blood mononuclear cells. If this were true, then small
molecule agonists of CRTH2 could potentially be used in the
management of preterm labour.
We have previously shown that 15dPGJ2 inhibits IL-1b induced
NF-kB activity in human amniocytes and myocytes through a
mechanism independent of the PPAR-c receptor [14]. 15dPGJ2 is
a CRTH2 agonist, and upregulates CD11b expression in
eosinophils via CRTH2 [36]. This led us to examine the effect
of a small molecule CRTH2 agonist, Pyl A, on NF-kB activity in
human amniocytes and myocytes. We saw no effect of Pyl A on
IL-1b stimulated p65 or phospho-p65 in either cell type (Figure 2).
We have also previously seen differing effects between 15dPGJ2
and Pyl A on NF-kB activity in the murine myometrium.
Intrauterine administration of 15dPGJ2 inhibits LPS induced
NF-kB in the murine myometrium and is associated with a delay
in preterm labour [16]. In contrast, Pyl A did not inhibit NF-kB
but instead augmented LPS stimulated NF-kB, which led to earlier
preterm delivery of the pups (unpublished data). Despite both
15dPGJ2 and Pyl A activating the CRTH2 receptor, cross talk
may exist between their other downstream targets of varying cell
types, which could explain their contrasting effects when given
in vivo.
Few studies have sought to characterise CRTH2 expression in
human gestational tissues. Helliwell et al examined mRNA
expression in amnion, choriodecidua and placental tissue [37].
They failed to detect CRTH2 in all 24 amnion samples, both
preterm and term. 3/12 preterm choriodecidual samples ex-
pressed CRTH2, all three had histological evidence of choriam-
nionitis, whereas 7/12 term samples expressed CRTH2. All
placental samples had detectable but variable levels of CRTH2
mRNA, with no difference between preterm and term samples.
Nagata et al have reported detectable CRTH2 mRNA in many
human tissue types including the placenta and non-pregnant
myometrium [24]. Since CRTH2 is classically expressed on
immune cells, it is plausible that the mRNA detected in these tissue
samples is from infiltrating leukocytes, which would explain why
CRTH2 can be detected choriodecidual samples associated with
chorioamnionitis.
Several studies have examined the presence of CRTH2 positive
T cells in the decidua in early pregnancy in association with the
potential CRTH2 mediated bias towards the anti-inflammatory
Th2 cytokine profile at the maternal fetal interface [38,39,40].
The percentage of CRTH2+ cells in CD4+/CD3+ cells are higher
in the decidua than the peripheral blood in early pregnancy [38].
It has been proposed that decidual Th2 cells are recruited to the
maternal fetal interface by PGD2 mediated chemoattraction via
the CRTH2 receptor [39]. In this study we examined CRTH2 at
the cellular level and found detectable levels of CRTH2 mRNA in
amniocytes and myocytes with three primer sets (Figure 3), using
choriodecidua and placental tissue and PBMCs as positive
controls. Expression levels were low with cycle numbers of
between 35 and 40 used for detection. This is consistent with
the low expression levels seen in other cell types such as monocytes
and dendritic cells, being amplified with up to 40 cycles [41].
To determine if the mRNA was translated into protein in
amniocytes and myocytes we used a polyclonal antibody against
the extracellular domain of CRTH2 intended for detection of
human CRTH2 at Mr,34 000 by immunoblot. This antibody
failed to convincingly detect CRTH2 in amniocyte and myocyte
protein lysate (Figure 4). Although a faint band was detected in
amniocytes and myocytes, no band was detected in the positive
control (PBMCs). Since no band was detected in the positive
control, we cannot conclude with this immunoblot if CRTH2 is
endogenously expressed or not. There are relatively few studies
that have used western analysis for the detection of human
CRTH2 by western analysis. Zayed et al detected bands at
Mr,41 000 and Mr,55 000 for chondrocytes, using osteoblasts
as a positive control [26]. However, they did not include blocking
or secondary antibody controls to confirm specificity. CRTH2 has
previously been demonstrated in osteoclasts by immunohisto-
chemistry with appropriate secondary antibody controls [42].
However, sale of this antibody has since been discontinued
because of non-specificity. Colombe et al detected a band for
CRTH2 in keratinocytes and melanocytes at Mr,45 000 with the
Figure 5. Detection of radiolabelled CRTH2 in pSG5 expression vector by x-ray and immunoblot. The in vitro transcription translation kit
was used with 35S Methionine to demonstrate the expression of CRTH2 and to provide a positive control for detection of CRTH2. A Mr,34 000
product was detected by x-ray (Lane 2). The progesterone expression vector was used as a control for the TNT kit (A). The protein lysate from the TNT
kit was subjected to western analysis; Negative Control: TNT kit with no plasmid DNA (lane 1), Negative control: Progesterone PSG5 Expression vector
(lane 2), Positive control: 35S Methionine labelled CRTH2 (Lane 3), Cold Methionine CRTH2 protein product (lane 4). Membranes were probed with 3
commercial antibodies; SC-23092 (B), SC-21798 (C), ProSci 4027 (D). None of the antibodies detected CRTH2.
doi:10.1371/journal.pone.0050734.g005
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Table 3. An overview of the mean fluorescence intensities and percentages in the gated cells during detection of endogenous
CRTH2 in lymphocytes, amniocytes and myocytes.
Endogenous expression No stain Isotype-PE CRTH2-PE
Lymphocytes 12.98 (MFI) 0.0 (%) 22.8 (MFI) 0.66 (%) 157.80 (MFI) 1.70 (%)
Amniocytes 13.91 (MFI) 0.46 (%) 15.71 (MFI) 0.80 (%) 14.41 (MFI) 0.47 (%)
Myocytes 71.38 (MFI) 2.06 (%) 69.30 (MFI) 1.44 (%) 69.69 (MFI) 1.25 (%)
doi:10.1371/journal.pone.0050734.t003
Figure 6. Flow cytometry for the detection of endogenous CRTH2. Lymphocytes were gated according to forward scatter and side scatter
and T helper cells were identified using CD4 as a cell surface marker (n = 6). A representative cytogram is presented with the right upper quadrant
showing CRTH2+/CD4+ lymphocytes (A). Histograms showing no staining, isotype control and CRTH2+ labelled lymphocytes (B), amniocytes (C) and
myocytes (D), (n = 5).
doi:10.1371/journal.pone.0050734.g006
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Figure 7. Flow cytometry for the detection of transfected CRTH2. Amniocytes (A) and myocytes (B) were transfected using gene juice and
electroporation respectively with CRTH2 PSG5 expression vector and labeled with anti-CRTH2-PE. A small shift to the right is seen in the histogram
showing expression of CRTH2 in transfected cells with an increase in the mean fluorescence intensity from 87.75 in the isotype control to 143.49 in
amniocytes, and from 68.84 to 96.97 in myocytes. An example of a GFP control is given for the myocyte transfection, with cells imaged with phase
contrast and with the fluorescent microscope to detect GFP transfected cells (C). A direct comparison is also shown with non-GFP transfected cells
(D).
doi:10.1371/journal.pone.0050734.g007
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same antibody, again without negative or secondary antibody
controls [28].
We cloned CRTH2 to provide a highly concentrated positive
control for detection by western analysis and flow cytometry.
CRTH2 was synthesized at the correct size of Mr,34 000
(Figure 5A), conforming roughly with the Kozak rule, and
consistent with the size determined by Nagata et al [19]. Nagata
et al raised three antibodies against CRTH2 which detected the
presumed glycosylated form of CRTH2 at Mr,55 000 and the
Mr,34 000 CRTH2 product following oligosaccharide cleavage
with Endo F, consistent with CRTH2 carrying N-glycosylation
sites as predicted by its amnio acid sequence.
Three commercially available antibodies failed to detect in vitro
translated CRTH2 by immunoblot (Figure 5B–D). CRTH2 has 7
transmembrane domains which is typical of the G protein coupled
seven transmembrane receptor superfamily. There are two
potential sites for N-glycosylation in the first extracellular domain,
and four consensus sites for protein kinase c phosphorylation on a
long cytoplasmic tail [19]. It is very likely that the antibodies
require the correct folding structure and/or post translational
modifications of the CRTH2 protein to bind to their epitopes. The
limitation of the cell free system is the inability to construct the
protein to its correctly folded structure or to reproduce the post-
translational modifications that exist in the cell, which may explain
why CRTH2 was not detected.
To overcome the limitation of the cell free system, we
transfected CRTH2 into amniocytes and myocytes. There are a
number of studies in which flow cytometry successfully detected
human CRTH2 on immune cells [19,31,32,38,43,44]. Since no
conclusion could be made on CRTH2 expression in amniocytes
and myocytes by immunoblot, we used flow cytometry to examine
CRTH2 expression on amniocytes and myocytes, using PBMCs as
a positive control. We used a monoclonal antibody raised against
the BM16 clone which has also successfully detected CRTH2 on
Table 4. An overview of the mean fluorescence intensities and percentages in the gated cells during detection of transfected
CRTH2 in amniocytes and myocytes.
Transfected expression No stain Isotype-PE CRTH2-PE
Amniocytes 45.20 (MFI) 0.04 (%) 87.75 (MFI) 0.26 (%) 143.49 (MFI) 0.62 (%)
Myocytes 63.88 (MFI) 0.69 (%) 68.84 (MFI) 3.82 (%) 96.97 (MFI) 8.03(%)
doi:10.1371/journal.pone.0050734.t004
Figure 8. The effect of 15dPGJ2 on basal NF-kB p65 phosphorylation in peripheral blood mononuclear cells. PBMCs were treated with
32 mM of 15dPGJ2 for 2 hours with or without preincubation with 2 mM of GSKCRTH2X for 45 mins. Whole cell protein lysate was examined for levels
of phosphorylated p65 (p-p65) using immunoblotting. A representative immunoblot from n=6 samples are shown (A). Immunoblots were reprobed
for b-actin as an internal loading control. Densitometric analysis of the immunoblots was conducted revealing a complete inhibition of p-p65 levels
with 15dPGJ2. Pre-incubation with the CRTH2 antagonist GSKCRTH2X had no effect on inhibition (B). J2 = 15dPGJ2, GSKX=GSKCRTH2X. Effect of
treatment was examined for statistical significance using ANOVA of repeated measures with Bonferroni’s multiple comparison test; **** P,0.0001.
doi:10.1371/journal.pone.0050734.g008
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non immune cells; human bronchial epithelial cells [27]. The
expression of CRTH2 is low in known cellular populations, with
between 0.4–6.5% of peripheral blood CD4+ cells expressing the
receptor [19]. Our data is consistent with this, with the
representative sample showing 2.5% of CD4+ cells expressing
CRTH2, (Figure 6B). This antibody did not detect endogenous
CRTH2 in amniocytes and myocytes (Figure 6C and 6D).
However, CRTH2 was detected at low levels in transfected cells
(Figure 7A and 7B). The pSG5 expression vector leads to high
expression of multiple proteins in myocytes [30], and good
transfection efficiency was achieved as demonstrated by the GFP
control (Figure 7C). Therefore, the inefficiency of amniocytes and
myocytes to express a stable CRTH2 protein supports our
conclusion that CRTH2 is not endogenously expressed in
amniocytes and myocytes.
The absence of CRTH2 on human amniocytes and myocytes
imply that the mechanism of 15dPGJ2 mediated inhibition of NF-
kB is independent of CRTH2. Moreover, the CRTH2 antagonist
failed to attenuate the effects of 15dPGJ2 in peripheral blood
mononuclear cells confirming that CRTH2 plays no role in NF-
kB inhibition (Figure 8). There are several signalling pathways
known to be involved upon CRTH2 activation and control the
varying effects of CRTH2 agonists. Indomethacin induces Ca2+
mobilization via CRTH2 in Th2 cells, which is inhibited by
pertussin toxin indicating a Ga/i dependent mechanism [45].
Indomethacin induced eosinophil morphological change and
upregulation of CD11b via CRTH2 can be attenuated with
inhibitors of MAP Kinase and phosphatidylinositol 3-kinase
(PI3K), suggesting an important role for these signalling pathways
in CRTH2 mediated effects [46]. PGD2 induces IL-4, IL-5 and
IL-13 production and cell migration in Th2 cells via CRTH2,
which is also attenuated by inhibiting the PI3K pathway [47]. The
only other study to explore the effect of CRTH2 agonists on NF-
kB showed that an IKB inhibitor had no effect PGD2 induced
cytokine production, however the NF-kB inhibitor rocaglamide
reduced PGD2 induced cytokine production by 30% [47]. The
authors of this study concluded that since PGD2 did not lead to an
increase phospho-IkB, a marker of NF-kB activation, that this
effect was likely to be non-pathway specific. Together with their
data showing no direct effect on NF-kB signalling upon CRTH2
activation with PGD2, our data also supports no direct effect on
NF-kB signalling with CRTH2 activation or inhibition (Figure 8).
The CRTH2 agonist 15dPGJ2 is an endogenous anti-inflam-
matory prostaglandin, formed from a non-enzymatic dehydration
of PGD2 [48]. It can accumulate intracellularly [49], and can be
measured endogenously in picomolar concentrations in body fluids
[50]. Although it is a high affinity ligand to the nuclear PPAR-c
receptor, 15dPGJ2 inhibits NF-kB independently of this receptor
in amniocytes and myocytes [14]. We have previously shown that
15dPGJ2 is able to inhibit multiple steps in the IKK/NF-kB
pathway. It inhibits IL-1b induced phosphorylation of IKKa and
IKKb, prevents IKBa degradation and thus prevents the release of
the NF-kB subunits for nuclear translocation [14]. Direct
modification of cysteine 179 of IKKb by covalent interaction by
15dPGJ2 has been demonstrated in HeLa cells [51].
15dPGJ2 contains an electrophilic cyclopenteneone ring, a
property which permits it to ligate nuclear receptors and modify
intracellular signalling molecules. The highly reactive ring of
15dPGJ2 can form a covalent interaction with several components
of the NF-kB signalling pathway (IkB kinase complex B, p50, and
p65 subunits) via the Michael reaction, resulting in impaired
nuclear entry, as described above, and impaired DNA binding
activity [52]. It is highly likely that the cyclopentenone ring is
essential for the inhibition of NF-kB seen in PBMCs in this study,
since we have previously shown the ability of PGA1, but not 9,10-
dihydro-15dPGJ2 (in which the ring is disrupted) to mimic the
effect of 15dPGJ2 in amniocytes and myocytes.
Despite the above mechanisms having been described, it is not
yet clear how 15dPGJ2 enters the cell to reach its targets, or if
there is an alternative receptor mediated mechanism. Although
Prostaglandin J2 has been shown to enter the cell by active
transport [53], it is not yet clear if this is the mechanism of entry of
15dPGJ2 into amniocytes, myocytes and PBMCs. In this study we
have excluded a CRTH2 dependent receptor mediated entry into
the cell as a requirement for NF-kB inhibition, and CRTH2
dependent downstream signalling effect on the inhibition of NF-
kB. Further studies should be carried out to investigate other
potential mechanisms of 15dPGJ2 mediated NF-kB inhibition,
including mechanism of entry into the cell, and to explore its effect
on the production of NF-kB regulated interleukins in amniocytes
and myocytes.
Conclusions
We have demonstrated that despite being able to detect low
levels of mRNA in amniocytes and myocytes, neither cell type
express CRTH2 at a detectable protein level. We conclude that
the mechanism of 15dPGJ2 mediated inhibition of NF-kB does
not involve CRTH2. Small molecule CRTH2 agonists are
therefore unlikely to be of value in the inhibition of inflammation
associated preterm birth.
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